SEP-363856
Total Payments
$4.6M
Transactions
4,373
Doctors
5
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $3.0M | 2,519 | 0 |
| 2019 | $1.1M | 1,336 | 0 |
| 2018 | $454,918 | 518 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.6M | 4,373 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia. | Sunovion Pharmaceuticals Inc. | $2.5M | 0 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis | Sunovion Pharmaceuticals Inc. | $1.7M | 1 |
| An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia | Sunovion Pharmaceuticals Inc. | $331,618 | 4 |
| A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia | Sunovion Pharmaceuticals Inc. | $128,158 | 0 |
| A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia. | Sunovion Pharmaceuticals Inc. | $11,676 | 0 |
| A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia | Sunovion Pharmaceuticals Inc. | $6,620 | 0 |
| A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia | Sunovion Pharmaceuticals Inc. | $6,223 | 0 |
| SEP361-116 | Sunovion Pharmaceuticals Inc. | $699.14 | 0 |
Top Doctors Receiving Payments for SEP-363856
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $4.6M
- Total Doctors 5
- Transactions 4,373
About SEP-363856
SEP-363856 is a drug associated with $4.6M in payments to 5 healthcare providers, recorded across 4,373 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..
Payment data is available from 2018 to 2020. In 2020, $3.0M was paid across 2,519 transactions to 0 doctors.
The most common payment nature for SEP-363856 is "Unspecified" ($4.6M, 100.0% of total).
SEP-363856 is associated with 8 research studies, including "A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia." ($2.5M).